Gastroenterology Research and Practice

Research Article

Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma

Table 1

ABCG2 expression and characteristics of patients.


	ABCG2 Expression		-value
	Positive ()	Negative ()	-value

Age
>50	14 (66.7%)	7 (70%)	0.992
≤50	7 (33.3%)	3 (30%)	0.992
Gender
Male	20 (95.2%)	6 (60%)	0.027
Female	1 (4.8%)	4 (40%)	0.027
HBsAg
Positive	14 (66.7%)	7 (70%)	0.992
Negative	7 (33.3%)	3 (30%)	0.992
AFP (ng/mL)
≤20	8 (38.1%)	2 (20%)	0.420
>20	13 (61.9%)	8 (80%)	0.420
TNM
I/II	15 (71.4%)	7 (70%)	1.000
III/IV	6 (28.6%)	3 (30%)	1.000
BCLC
0/A	10 (47.6%)	7 (70%)	0.280
B/C/D	11 (52.4%)	3 (30%)	0.280
Differentiation
Poor	3 (16.7%)	1 (10%)	1.000
Moderate-Well	18 (83.3%)	9 (90%)	1.000
Tumor number
Single	17 (81.0%)	8 (80%)	1.000
Multiple	4 (19.0%)	2 (20%)	1.000
Tumor size
<5	9 (42.9%)	5 (50%)	1.000
≥5	12 (57.1%)	5 (50%)	1.000
Microvascular invasion
Present	8 (38.1%)	3 (30%)	0.996
Absent	13 (61.9%)	7 (70%)	0.996
Macrovascular invasion
Present	6 (28.6%)	1 (10%)	0.379
Absent	15 (71.4%)	9 (90%)	0.379
Milan
In	8 (38.1%)	5 (50%)	0.700
Out	13 (61.9%)	5 (50%)	0.700
Ki67
≤20%	9 (42.9%)	6 (60%)	0.458
>20%	12 (57.1%)	4 (40%)	0.458

AFP: α-fetoprotein; TNM: TNM staging system of the International Union Against Cancer; BCLC: Barcelona Clinic Liver Cancer staging system; Milan: Milan criteria.